Login / Signup

Efficacy and safety of mirabegron for the treatment of neurogenic detrusor overactivity-Prospective, randomized, double-blind, placebo-controlled study.

Jan KrhutVladimír BorovičkaKarolína BílkováRadek SýkoraDavid MíkaJan MokrišRoman Zachoval
Published in: Neurourology and urodynamics (2018)
Mirabegron (50 mg) improved both urodynamic variables and patient-reported outcomes in patients with NDO. The treatment was tolerated well.
Keyphrases
  • double blind
  • patient reported outcomes
  • placebo controlled
  • clinical trial
  • phase iii
  • open label
  • phase ii
  • study protocol
  • botulinum toxin
  • replacement therapy